TRINETRA › Sectors › Healthcare
Aarti Drugs Limited (AARTIDRUGS) — share price, P/E and fundamentals
Aarti Drugs Limited (NSE: AARTIDRUGS) closed at ₹435.20 on 30 Oct 2026, -15.9% over one year, against a 52-week range of ₹318.95 – ₹534.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 31 Jul 2026) it reported revenue of ₹703 cr and net profit of ₹50 cr, a 7.1% net margin; revenue grew 19.0% and profit grew 35.5% year on year.
On four consecutive filed quarters its trailing P/E is 20.8; since 12 May 2025 its own P/E has ranged from 14.4 to 29.7 (median 20.7), and today's reading is higher than 51% of those 364 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 13.0%, ROCE 16.6%, debt-to-equity 0.37, Piotroski F-score 7 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 17% of 64 sector peers; PBT margin higher than 16% of 64 sector peers; ROE higher than 45% of 64 sector peers.
Key figures
| Last close | ₹435.20 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -0.5% / +18.7% / -15.9% |
| 52-week low – high | ₹318.95 – ₹534.00 |
| Market capitalisation | ₹3,972 cr |
| Trailing P/E | 20.8 |
| Price / book | 2.56 |
| EV / EBITDA | 13.6 |
| Earnings yield | 4.8% |
| TTM EPS | ₹20.95 |
| TTM net profit | ₹191 cr |
| Quarter revenue | ₹703 cr |
| Quarter net profit | ₹50 cr |
| Net margin | 7.1% |
| Revenue growth (YoY) | +19.0% |
| Profit growth (YoY) | +35.5% |
| Return on equity | 13.0% |
| ROCE | 16.6% |
| Debt / equity | 0.37 |
| Current ratio | 1.59 |
| Free cash flow | ₹80 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹5.8 cr |
Against Healthcare peers
| Metric | AARTIDRUGS | Peer median | Percentile |
|---|---|---|---|
| Net margin | 7.14 | 12.89 | 17 |
| PBT margin | 9.85 | 17.68 | 16 |
| ROE | 12.96 | 13.87 | 45 |
| ROCE | 16.58 | 17.26 | 48 |
| Debt / equity | 0.37 | 0.11 | 76 |
| Cash conversion | 1.30 | 1.25 | 53 |
| Trailing P/E | 20.78 | 43.26 | 8 |
| P/B | 2.56 | 6.02 | 8 |
Questions
What is the P/E ratio of Aarti Drugs Limited?
Aarti Drugs Limited's trailing P/E is 20.8, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 12 May 2025 its P/E has ranged 14.4–29.7.
What were Aarti Drugs Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Aarti Drugs Limited reported revenue of ₹703 cr and net profit of ₹50 cr (consolidated), filed with the exchange on 31 Jul 2026.
What is Aarti Drugs Limited's ROE?
Return on equity is 13.0% based on the balance sheet dated 31 Mar 2026.
Does Aarti Drugs Limited have debt?
Debt-to-equity is 0.37 on the balance sheet dated 31 Mar 2026.
What is AARTIDRUGS's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, AARTIDRUGS traded between ₹318.95 and ₹534.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.